Business
Immunome Reports First Quarter 2021 Financial Results
- IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND
About this update from Immunome, Inc.
[{"type":"text","content":"\n- IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing -\n\n- IMM-ONC-01: Advanced proprietary antibody against IL-38, a novel innate immune checkpoint, into IND-enabling studies -\n\n- Dennis Giesing, Ph.D. appointed as Chief Development Officer and Corleen Roche appointed as Chief Financial Officer -\n\n- Raised $27 million in gross proceeds in a private placement -\n\n EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.\n\nFirst Quarter and Subsequent Highlights\n\n\nIMM-BCP-001: In February 2021, Immunome announced that it discovered antibodies capable of neutralizing multiple SARS-CoV-2 variants, including the South African Variant, in pseudovirus testing. In April 2021, the company announced antibody selection for its IMM-BCP-01 cocktail and shared data showing that IMM-BCP-01 neutralizes CDC SARS-CoV-2 \"Variants of Concern\" in preclinical testing. The cocktail was efficacious in Syrian hamsters infected with SARS-CoV-2 (USA-WA1/2020) in both prophylactic and treatment schedules. Further, the cocktail neutralized South Africa and UK variants in live virus testing and Brazil and California variants in pseudovirus testing. An Investigational New Drug (IND) filing for IMM-BCP-001 is planned for late 2Q/early 3Q 2021.\n\n\nIMM-ONC-001: In March 2021, Immunome announced its proprietary antibody against IL-38 advanced into IND-enabling studies. Based on Immunome’s research findings, IL-38 functions as a novel innate immune checkpoint that inhibits infiltration and pro-inflammatory activity of innate immune cells. The company’s analysis also suggests that IL-38 is over-expressed in certain tumors and is potentially linked to reduced infiltration of innate immune cells. Immunome anticipates filing an IND for this product candidate in 2H 2021.\n\n\nAppointed Dr. Dennis Giesing as Chief Development Officer and Corleen Roche as Chief Financial Officer. In March 2021, the company announced the appointment of Dennis Giesing, Ph.D. to the role of Chief Deve...